Reading a term sheet

📖 14 min read · 🎯 Seed → Series B · Updated April 2026

A term sheet is split into two halves: economics (who gets what when there's an exit) and control (who decides what along the way). Read both lenses on every clause.

Economics

Pre-money valuation

The number that gets the headlines. Pre-money + investment = post-money. Investor's % = investment / post-money. Always do this math yourself — don't rely on the term sheet's stated %.

Liquidation preference

Order of payout when the company sells. 1× non-participating is standard at seed: the investor gets their money back first, then either takes the preference or converts to common — never both. 2× participating means the investor gets 2× their money back AND their pro-rata of the rest. Avoid at seed; expect heavy push at Series B+.

The senior-junior stack matters. If your Series A has 1×, but the Series B negotiates 2× participating senior to A, your A investor loses out and so do you. Push for "pari passu" (equal seniority) preferences.

Anti-dilution

Broad-based weighted average is fair and standard. Full ratchet means if you raise the next round at a lower price, the investor's price gets reset to that price — incredibly punitive on a down round. Reject full ratchet at any stage.

Pro-rata rights

The investor's right to buy enough of your next round to maintain their %. Standard for institutional investors. Cap pro-rata to investors with >5% to avoid 14 angels each demanding allocation in your next round.

ESOP top-up

Investors will require a refreshed ESOP pool, sized so it dilutes founders pre-money, not the new money. 10–15% pool at seed, 15–20% by Series A. Negotiate the size — most term sheets quote a number that's 2–3% above what's needed.

Control

Board composition

At seed, a 3-person board is common: 1 founder, 1 lead investor, 1 independent (mutually agreed). At Series A, expect 5: 2 founders, 2 investors, 1 independent. Lock down the independent's nomination process — "mutually agreed" beats "investor's choice".

Protective provisions

Investor consent required for: sale of company, fundraise, budget approval, executive hiring, debt above $X, related-party transactions. Standard. Push back on: dividend payment veto (irrelevant at this stage), product-roadmap consent (none of their business), individual hire vetoes below VP level.

Drag-along

Forces minority shareholders to sell if a majority approves. Standard. Negotiate the trigger — "majority of preferred + majority of common" is fair; "investor majority alone" gives away too much.

Founder vesting

4 years, 1-year cliff, restarted at the round. Yes, even on shares you already own. Investors want commitment. Push for credit for time already served — typically 1 year of immediate vesting at signing. Without this, you've effectively reset to year zero.

No-shop / exclusivity

You agree not to talk to other investors for 30–60 days. Acceptable post-term-sheet. Avoid pre-term-sheet exclusivity — it's a stalling tactic.

The four-clause showdown

If you can negotiate only four things, in order:

  1. Liquidation preference — must be 1× non-participating at seed.
  2. ESOP size — every 5% you save is a 5% founder dilution avoided.
  3. Vesting credit — 1+ year credit at signing is your sanity insurance.
  4. Anti-dilution — broad-based weighted average, never full ratchet.
Read the SHA, not just the term sheet. The term sheet is non-binding (mostly). The Shareholders' Agreement is what actually governs you. Your lawyer should redline the SHA against the term sheet, not just review it.

Related guides